ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Case Report: Lymphocytic Vasculitis of the Central Nervous System

Gbemisola Olayemi, MD, Evangeline Scopelitis, MD, & Jerald M. Zakem, MD  |  January 17, 2019

Vasculitis is a group of chronic inflammatory diseases in which the blood vessel is the target of an immune reaction. They can be secondary to connective tissue disease, idiopathic or due to infection, neoplasm or drugs.1 Primary angiitis of the central nervous system (PACNS) is a rare syndrome characterized by inflammatory cell infiltration and necrosis…

Filed under:ConditionsVasculitis Tagged with:central nervous system vasculitiscyclophosphamideMethylprednisolonePrimary Angiitis of the Central Nervous System

Medicare Changes Could Have Some Patients Paying More for Drugs

Lisa Rapaport  |  January 15, 2019

(Reuters Health)—A proposed shift in Medicare coverage for medicines administered by doctors may help reduce total drug spending, but a new study suggests it may also lead to higher out-of-pocket costs for some patients. Right now, drugs given by infusion or injection in outpatient settings are covered by Medicare Part B, which is part of…

Filed under:Drug Updates Tagged with:drug costsMedicareMedicare Part BMedicare Part D

Updated ACP Ethics Manual Provides 6-Step Approach to Dilemmas

Will Boggs, MD  |  January 15, 2019

NEW YORK (Reuters Health)—The 2019 edition of the American College of Physicians (ACP) ethics manual provides a six-step approach to resolving ethical dilemmas and adds or expands sections that address emerging issues in 21st century medicine.1 “The Manual provides succinct guidance on issues that affect the patient-physician relationship, and also issues that have to do…

Filed under:EthicsProfessional Topics Tagged with:EthicsSocial Mediatelemedicine

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

Michele B. Kaufman, PharmD, BCGP  |  January 14, 2019

In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab…

Filed under:Drug Updates Tagged with:adalimumabixekizumabPsApsoriatic arthritis

New York City Launches $100 Million Universal Health Insurance Program

Gina Cherelus  |  January 10, 2019

NEW YORK (Reuters)—New York City has launched a $100 million health insurance program to cover 600,000 uninsured residents, including those unable to afford coverage and those living in the United States illegally, Mayor Bill de Blasio said on Tuesday. De Blasio, now in his second term as mayor of the country’s most populous city, has…

Filed under:Professional Topics Tagged with:Mayor Bill de BlasioNew York CityNYC Care planuniversal health insurance program

A Step Further: Results from the 1st ACR/ARHP Annual Meeting Walking Challenge

Carina Stanton  |  January 8, 2019

With more than 152,000 taken steps in four days, top honors in the first-ever ACR/ARHP Annual Meeting Walking Challenge go to Mark Phelan, MD…

Filed under:Professional Topics Tagged with:ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)ExercisewalkingWalking Challenge

Intronic Polymorphism Associated with Risk of Neurological Disorders in SLE

Lara C. Pullen, PhD  |  January 8, 2019

Patients who develop neuropsychiatric symptoms of SLE have a small nucleotide polymorphism (SNP) in an intron in a Ca++ ion channel gene that influences some, but not all, events regulated by Ca++. The SNP appears to influence activation induced apoptosis rates and cytokine production, specifically IL-4, in a disease- and genotype-specific manner…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:brainneurological disordersNeurologySLEsystemic lupus erythematosus (SLE)

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 7, 2019

The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAfilgotinibRheumatoid Arthritis (RA)rituximabrituximab-abbsU.S. Food and Drug Administration (FDA)

SLE Patients May Not Receive Enough Cardiovascular Disease Assessment & Treatment

Arthritis Care & Research  |  January 2, 2019

Systemic lupus erythematosus (SLE) is associated with high rates of cardiovascular disease. However, research has shown that aggressive risk assessment with lipid screenings and treatment with statins may be suboptimal for these patients. A new study compared the rates of screening and treatment between SLE patients, diabetes mellitus patients and the general Medicaid population. The results: Despite having an elevated risk of CVD, SLE patients received less lipid testing and fewer statin prescriptions than other patients…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Arthritis Care & Research

Moderate Liver Enzyme Elevation Found in Patients With & Without Hepatic Steatosis

Carina Stanton  |  January 2, 2019

Limited data are available on liver enzyme elevation in patients with RA, PsA and psoriasis being treated with tofacitinib and methotrexate. But early study findings are shedding light on the nature and risks of liver enzyme levels in these patients…

Filed under:Conditions Tagged with:fatty liver diseasehepatic steatosisliverliver enzyme levelsTofacitinib

  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 329
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences